Talk:Familial amyloid polyneuropathy

Medicine: Dermatology / Genetics Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Dermatology task force.
	This article is supported by the Medical genetics task force.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Familial amyloid polyneuropathy.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Familial amyloid neuropathy

Is 'familial amyloid polyneuropathy' the same disease as 'familial amyloid neuropathy'? If yes, the articles should be merged. If no, some distinction should be made in the articles, at least with a hatnote. --Eleassar ^{my talk} 10:03, 13 June 2010 (UTC)[reply]

sources

maybe useful to develop some content from these:

Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs. 2014 Sep;23(9):1239-51. doi: 10.1517/13543784.2014.922541. Epub 2014 Jul 8. Review. PMID 25003808

Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol. 2014 Jun;261(6):1227-33. doi: 10.1007/s00415-014-7373-0. Epub 2014 Jun 3. Review. PMID 24888313

Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014 Jun;39(3):225-33. doi: 10.1111/jcpt.12145. Review. PMID 24749898

Yin J, et al Chinese familial transthyretin amyloidosis with vitreous involvement is associated with the transthyretin mutation Gly83Arg: a case report and literature review. Amyloid. 2014 Jun;21(2):140-2. doi: 10.3109/13506129.2014.892871. Epub 2014 Mar 6. Review. PMID 24601824

Adams D, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014 Mar;14(3):435. doi: 10.1007/s11910-013-0435-3. Review. PMID 24482069

Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014 Mar;11(1):50-7. doi: 10.1007/s11897-013-0182-4. Review. PMID 24464360

Aljaroudi WA et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014 Apr;21(2):271-83. doi: 10.1007/s12350-013-9800-5. Review. PMID 24347127

Mohty D, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23. Review. PMID 24070600

Planté-Bordeneuve V, Kerschen P. Transthyretin familial amyloid polyneuropathy. Handb Clin Neurol. 2013;115:643-58. doi: 10.1016/B978-0-444-52902-2.00038-2. Review. PMID 23931808

Ando Y, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. doi: 10.1186/1750-1172-8-31. Review. PMID 23425518

yep Jytdog (talk) 18:00, 23 March 2015 (UTC)[reply]

Senile systemic amyloidosis?

The lead section says that "FAP is distinct from senile systemic amyloidosis", yet Senile systemic amyloidosis redirects to this article. Why not separate articles about the two, particularly since (despite the redirect) there is nothing in this article, other than the the lead-section sentence, where senile systemic amyloidosis is mentioned? -- John Broughton (♫♫) 18:39, 9 June 2015 (UTC)[reply]

Sort of a discussion

at Wikipedia_talk:Identifying_reliable_sources_(medicine)#Time_to_play_the_fake_secondary_source_game Jytdog (talk) 05:20, 13 September 2018 (UTC)[reply]

Well, the drug tafamidis was just approved by the FDA for treatment of ATTR cardiomyopathy, in May. Jytdog has been banned from Wikipedia.

And this article still has no informaton about the NEJM study, because you wouldn't let me add it last September. Happy with yourselves? I'm just checking in to see. S B H arris 04:51, 23 July 2019 (UTC)[reply]